These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 21923598)

  • 21. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 22. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles.
    Noah L
    Jurimetrics; 2002; 43(1):1-28. PubMed ID: 17333591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
    Avery M
    Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Payer perspectives on pharmacogenomics testing and drug development.
    Epstein RS; Frueh FW; Geren D; Hummer D; McKibbin S; O'Connor S; Randhawa G; Zelman B
    Pharmacogenomics; 2009 Jan; 10(1):149-51. PubMed ID: 19102724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical trademarks: navigating through the FDA's pilot program.
    Ferrer E
    Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The food and drug administration and molecular imaging agents: potential challenges and opportunities.
    Henderson JA; Alexander BC; Smith JJ
    J Am Coll Radiol; 2005 Oct; 2(10):833-40. PubMed ID: 17411943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments.
    Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Black box warnings: what do they mean to pharmacists and patients.
    Martin CM; Borgelt L
    Consult Pharm; 2012 Jul; 27(7):482-92. PubMed ID: 22910129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ethical implications of stratifying by race in pharmacogenomics.
    Lee SS
    Clin Pharmacol Ther; 2007 Jan; 81(1):122-5. PubMed ID: 17186010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics and warfarin therapy.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA drug classification system.
    Sanborn MD; Godwin HN; Pessetto JD
    Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenomics: the genomics of drug response.
    March R
    Yeast; 2000 Apr; 17(1):16-21. PubMed ID: 10797598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA policy on unapproved drug products: past, present, and future.
    Chhabra R; Kremzner ME; Kiliany BJ
    Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug advisory committees. Getting outside advice for close calls.
    Farley D
    FDA Consum; 1995 Mar; 29(2):23-6. PubMed ID: 10172354
    [No Abstract]   [Full Text] [Related]  

  • 39. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
    Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ
    Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
    Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.